Annual Report

The report presents 2006 as a year of expansion: Beximco Pharma launched 58 products and entered three new overseas markets. It highlights the completed conversion of its metered-dose inhaler plant to HFA-based CFC-free production and completion of two lines at its USFDA-approvable oral solid dosage facility. The company also reports 11.3% sales growth to Tk. 3,702.32 million and export sales growth of 29.5%.